TY - JOUR
T1 - Prevalence and Predictors of Third-Generation Cephalosporin Resistance in the Empirical Treatment of Spontaneous Bacterial Peritonitis
AU - Sunjaya, Dharma B.
AU - Lennon, Ryan J.
AU - Shah, Vijay H.
AU - Kamath, Patrick S.
AU - Simonetto, Douglas A.
N1 - Funding Information:
Grant Support: This project was funded through the Small Grant Program 2017 (Mayo CCaTS grant no. UL1TR000135). Potential Competing Interests: Dr Shah is a consultant to Novartis Pharma, Durect Corp, Merck Research Laboratories, Enterome Vital Therapies, and Afimmune Ltd. Dr Kamath is a consultant and has received grants, royalties, and other payments fom Sequana Medical. The other authors report no competing interests.
Publisher Copyright:
© 2019 Mayo Foundation for Medical Education and Research
PY - 2019/8
Y1 - 2019/8
N2 - Objective: To better characterize the changing patterns of spontaneous bacterial peritonitis (SBP) in a tertiary academic center in the United States by identifying the prevalence of gram-positive organisms and cephalosporin resistance along with predictors of mortality and antibiotic drug resistance. Patients and Methods: We reviewed 481 consecutive patients with SBP at Mayo Clinic in Rochester, Minnesota, from January 1, 2005, through December 31, 2016. Data on comorbid conditions, etiology of cirrhosis, factors predisposing to infection, and antimicrobial and antibiotic drug use were collected. Results: We identified 96 patients (20%) with culture-positive SBP requiring treatment (median age, 60 years; age range, 22-87 years; 44% men). Gram-positive organisms account for more than half of the cases. Overall resistance to third-generation cephalosporins was 10% (n=10). Risk factors for third-generation cephalosporin resistance include nosocomial acquisition, recent antibiotic drug use, and hepatocellular carcinoma. The negative predictive value for antibiotic drug resistance in the present model was 96% (70 of 73). Overall mortality at 30 and 90 days was 23% and 37%, respectively. Conclusion: These findings support the recent observation of a rising prevalence of gram-positive organisms in SBP. Despite the changing pattern, third-generation cephalosporins seem to provide adequate empirical treatment in patients with community-acquired and health care–associated SBP without hepatocellular carcinoma.
AB - Objective: To better characterize the changing patterns of spontaneous bacterial peritonitis (SBP) in a tertiary academic center in the United States by identifying the prevalence of gram-positive organisms and cephalosporin resistance along with predictors of mortality and antibiotic drug resistance. Patients and Methods: We reviewed 481 consecutive patients with SBP at Mayo Clinic in Rochester, Minnesota, from January 1, 2005, through December 31, 2016. Data on comorbid conditions, etiology of cirrhosis, factors predisposing to infection, and antimicrobial and antibiotic drug use were collected. Results: We identified 96 patients (20%) with culture-positive SBP requiring treatment (median age, 60 years; age range, 22-87 years; 44% men). Gram-positive organisms account for more than half of the cases. Overall resistance to third-generation cephalosporins was 10% (n=10). Risk factors for third-generation cephalosporin resistance include nosocomial acquisition, recent antibiotic drug use, and hepatocellular carcinoma. The negative predictive value for antibiotic drug resistance in the present model was 96% (70 of 73). Overall mortality at 30 and 90 days was 23% and 37%, respectively. Conclusion: These findings support the recent observation of a rising prevalence of gram-positive organisms in SBP. Despite the changing pattern, third-generation cephalosporins seem to provide adequate empirical treatment in patients with community-acquired and health care–associated SBP without hepatocellular carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=85068581374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068581374&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2018.12.036
DO - 10.1016/j.mayocp.2018.12.036
M3 - Article
C2 - 31303428
AN - SCOPUS:85068581374
SN - 0025-6196
VL - 94
SP - 1499
EP - 1508
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 8
ER -